Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jasmonic Acid SCHEMBL1365045 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL114054 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL7113180 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL125395 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL12216372 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL7113179 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL3074832 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL5598513 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL1365044 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Jasmonic Acid SCHEMBL6734659 | 1.00 | AKR1C4 (1.00) | AKR1C4AKR1C3AKR1C2HTTPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247604-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | FIRMENICH SA (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20220142158-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2022-05-12 | — | — | US | claimed |
| EP-3930460-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2022-01-05 | — | — | EP | claimed |
| CN-112638861-A | Process for preparing cis-alpha, beta-substituted cyclopentanones | 弗门尼舍有限公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020239954-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2020-12-03 | — | — | WO | claimed |
| WO-2012034825-A3 | FLUORINE GAS PLANT | SOLVAY SA (BE) | 2012-05-10 | — | — | WO | claimed |
| EP-1333022-B1 | Compounds containing derivatives of cyclopentane and their use to stimulate skin peeling | OREAL (FR) | 2011-12-07 | — | — | EP | claimed |
| US-20030224024-A1 | Compositions comprising cyclopentane derivatives and their use | L'OREAL S.A. (FR) | 2003-12-04 | — | — | US | claimed |
| EP-1333022-A2 | Compounds containing derivatives of cyclopentane and their use to stimulate skin peeling | L'OREAL (FR) | 2003-08-06 | — | — | EP | claimed |
| EP-0743985-B1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH & CIE (CH) | 2000-10-11 | — | — | EP | claimed |
| US-5667995-A | MICROORGANISM CULTURE, BETA-OXIDATION, BIOSYNTHESIS | FIRMENICH SA (CH) | 1997-09-16 | — | — | US | claimed |
| US-20240336662-A1 | COMPOSITIONS AND RELATED METHODS FOR MODULATING ALKALOID PRODUCTION BY CONTROLLING PMT PROMOTER ACTIVATION MEDIATED BY TRANSCRIPTIONAL FACTORS ERF AND MYC | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-10 | — | — | US | disclosed |
| US-12054523-B2 | Compositions and related methods for modulating alkaloid production by controlling PMT promoter activation mediated by transcriptional factors ERF and Myc | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-06 | — | — | US | disclosed |
| US-12018226-B2 | Perfuming compositions | FIRMENICH SA (CH) | 2024-06-25 | — | — | US | disclosed |
| EP-4378921-A1 | USE OF FA-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2024-06-05 | — | — | EP | disclosed |
| EP-0743985-B1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH & CIE (CH) | 2000-10-11 | — | — | EP | disclosed |
| US-5667995-A | MICROORGANISM CULTURE, BETA-OXIDATION, BIOSYNTHESIS | FIRMENICH SA (CH) | 1997-09-16 | — | — | US | disclosed |
| US-5667995-A | MICROORGANISM CULTURE, BETA-OXIDATION, BIOSYNTHESIS | FIRMENICH SA (CH) | 1997-09-16 | — | — | US | disclosed |
| EP-0743985-A1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH SA (CH) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996018742-A1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH S.A. (CH) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224024-A1 | Compositions comprising cyclopentane derivatives and their use | CBR1, CBR3, DECR1 | AKR1C4 34/4885AKR1C3 23/4885AKR1C2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.